Research and Innovation

The Mass General Bleeding Disorders Center maintains a list of current research studies that may benefit our bleeding disorder patients.

Current Studies

• American Thrombosis and Hemostasis Network (ATHN) – partners with HTCs around the country to facilitate studies to gain a better understanding of the issues affecting people with bleeding and clotting disorders
• Women and Girls with Bleeding Disorders research studies focusing on women and girls with bleeding disorders
• CDC Community Counts: In collaboration with the CDC, this public health monitoring program aims to better understand the health issues that affect people with hemophilia and rare bleeding disorders. We do this by monitoring and keeping record of our participants health status.
• ATHN Transcends: Hemophilia Natural History Arm: In collaboration with the American Thrombosis and Hemostasis Network (ATHN), and through observational research, we look to understand the safety and effectiveness of current treatments of hemophilia to improve care in the future.
• ATHN Transcends: PUPs Matter Arm: With ATHN, this study focuses on the development of inhibitors and the health risks in Previously Untreated Patients (PUPs) with less than 50 exposure days to current therapies. Our goal is to provide a platform for ongoing and future clinical trials to improve the outcomes of this vulnerable population.
• Fitusiran Clinical Trials: Fitusiran is a non-factor, investigational RNA interference agent used to treat both Hemophilia A and Hemophilia B patients with and without inhibitors. Fitusiran, a once-a-month, subcutaneous injection, decreases antithrombin and increases thrombin (a naturally occurring clotting protein). More information can be found here.
• VWD Study: The Role of the VWF Propeptide in Platelet Adhesion/Aggregation and Associated Fibrin Formation in Flowing Blood from Patients with Type 1 Von Willebrand Disease - This MGH physician-scientist driven study aims to compare efficacy of two different types of VWF factor concentrates (Humate-P vs Vonvendi) through novel platelet analysis methods.